Beta Blocker Management for Tachycardia

Introduction to Beta Blocker Therapy

The American Heart Association recommends beta blockers as first-line medications for rate control, with metoprolol being particularly effective, achieving heart rate endpoints in 70% of patients 1

Intravenous propranolol is specifically recommended by ACC/AHA/HRS guidelines for junctional tachycardia (Class IIa, Level C-LD) 2, 3, 4
Propranolol was found modestly effective in terminating and/or reducing the incidence of junctional tachycardia in adult case series 2
The addition of procainamide to propranolol may be more effective than propranolol monotherapy 2, 3
IV beta blockers should only be used in hemodynamically stable patients 5, 6

The American College of Cardiology recommends metoprolol 25-100 mg BID (immediate release) or 50-400 mg daily (extended release) for ongoing rate control 1
Oral beta blockers are reasonable for ongoing management of junctional tachycardia (Class IIa, Level C-LD) 2, 3, 4
Beta blockers are preferred as first-line chronic therapy because of the important proarrhythmic effects and long-term toxicity of alternative agents 2, 3, 4

IV beta blockers are reasonable for acute treatment in hemodynamically stable patients with AVNRT (Class IIa, Level B-R) 5, 6
Diltiazem is more effective than esmolol for terminating AVNRT, but beta blockers have an excellent safety profile 5
Oral verapamil or diltiazem is actually preferred over beta blockers for ongoing AVNRT management (Class I, Level B-R) 5

Avoid beta blockers in patients with decompensated heart failure, pre-excited atrial fibrillation/flutter, AV block greater than first degree, SA node dysfunction, and Wolff-Parkinson-White syndrome with tachycardia 1

Assess heart rate control both at rest and during activity 1
Monitor for hypotension, bradycardia, and heart failure exacerbation 1
When paroxysmal tachycardia is present, avoid potential for bradyarrhythmias and hypotension when initiating therapy 2, 3, 4
Combination therapy may be needed for refractory cases, but monitor closely for excessive bradycardia 1

In patients with diabetes, beta blockers may mask symptoms of hypoglycemia, which normally include tachycardia from sympathetic nervous system activation, according to the American Heart Association 7
Beta blockers are routinely given after cardio-defibrillator implantation and in tachy-bradycardia syndrome to suppress attacks of tachycardia, as recommended by the American College of Cardiology 8

The European Society of Cardiology recommends metoprolol 2.5-10 mg IV bolus over 2 minutes, repeated as required, for acute symptomatic palpitations, with esmolol as an alternative for ultra-short acting control 9, 10
For patients with mitral valve prolapse experiencing palpitations, beta blockers are the treatment of choice, with cessation of stimulants often sufficient 11

The European Society of Cardiology lists bisoprolol, carvedilol, and nebivolol as acceptable beta blockers for rate control, with specific dosing recommendations 9, 10
Beta blockers are contraindicated in patients with decompensated heart failure, pre-excited atrial fibrillation/flutter, AV block greater than first degree, and severe bronchospasm, as stated by the European Heart Journal 10
The European Society of Cardiology recommends avoiding beta blockers in patients with SA node dysfunction and severe bronchospasm, but notes that beta-1 selective agents like metoprolol or bisoprolol are safer than carvedilol 9, 10

For patients with reduced ejection fraction (LVEF <40%), beta blockers remain first-line, but diltiazem and verapamil should be avoided due to negative inotropic effects, as recommended by the European Society of Cardiology 9, 10
The American Heart Association recommends verapamil or diltiazem over beta blockers for AVNRT, with beta blockers as a Class IIa option 12
The European Society of Cardiology notes that beta blockers may mask hypoglycemia symptoms in diabetic patients, and recommends counseling patients accordingly 9, 10

The European Society of Cardiology recommends assessing heart rate control both at rest and during activity, and monitoring for hypotension, bradycardia, and heart failure exacerbation 9, 10
Common adverse effects of beta blockers include lethargy, headache, peripheral edema, upper respiratory symptoms, gastrointestinal upset, and dizziness, which are generally mild and dose-dependent, as reported by the European Heart Journal 9, 10